{"filings":[{"id":805638,"accession_number":"0001193125-26-253435","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2026-06-02T20:01:13+00:00","items":["5.07"],"status":"ready","headline":"Tyra Biosciences elects three Class II directors, ratifies Ernst & Young as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Habib J. Dable, Susan Moran, and Robert More elected Class II directors for three-year terms.","Robert More received 41,013,686 for and 3,705,719 withheld (8.3% withheld); Dable and Moran had under 1.1% withheld.","Ernst & Young ratification: 53,092,820 for, 1,316 against, 3,246 abstentions; no broker non-votes on this proposal.","Broker non-votes on director election: 8,377,977 for each director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50404,"accession_number":"0001193125-26-220638","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2026-05-13T12:00:44+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q1 net loss $39.3M; cash $383.5M; SURF302 data August 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.3M vs $28.1M YoY; R&D expenses $33.5M (+34%) driven by dabogratinib trials.","Cash, equivalents & marketable securities $383.5M; runway into 2H 2028.","First patient dosed in LG-UTUC trial SURF303 (pivotal); initial results expected 2027.","Initial SURF302 data (IR NMIBC) due August 2026; BEACH301 safety sentinel data Q4 2026.","Appointed Habib Dable to Board; raised $147.9M net via ATM in Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96368,"accession_number":"0001193125-26-160347","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2026-04-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tyra Biosciences expands board to ten, appoints Habib J. Dable as Class II director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board increased from nine to ten members; Dable appointed effective April 16, 2026, with term expiring at 2026 annual meeting.","Dable previously President & CEO of Acceleron Pharma (acquired by Merck in 2021) and advisor at RA Capital since April 2022.","Received option to purchase 44,400 shares vesting equally over 36 months; cash compensation per Non-Employee Director Program.","Board determined Dable is independent under Nasdaq listing requirements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96367,"accession_number":"0001193125-26-140027","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tyra Biosciences designates VP Finance Julia Rueb as principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Julia Rueb (VP Finance) appointed principal accounting officer effective April 1, 2026, succeeding CFO Alan Fuhrman.","Fuhrman continues as principal financial officer; Rueb has been with the company since 2022.","Rueb is a CPA with prior roles at SOAProjects and Ernst & Young; no family ties to directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110221,"accession_number":"0001193125-26-091880","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2026-03-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tyra Biosciences raises $126M via block sale of 4M shares at $31.50 each","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 4M common shares at $31.50/share to a large investment management firm for $126M gross proceeds.","Block trade executed under existing ATM program registered on Form S-3; no public offering discount disclosed.","Net proceeds after fees and expenses are undisclosed; use of proceeds not specified in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110220,"accession_number":"0001193125-26-085399","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences reports FY2025 net loss of $119.9M; cash $256M, outlines dabogratinib 3x3 strategy","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 net loss $33.8M vs $25.6M; FY net loss $119.9M vs $86.5M; R&D spend rose to $102.9M.","Cash, equivalents and marketable securities $256.0M at Dec 31, 2025; runway through at least 2027.","Launched 'dabogratinib 3x3' strategy: three pivotal-ready studies in LG-UTUC, IR NMIBC, and ACH.","SURF302 (IR NMIBC) initial 3-month CR data expected by end 1H 2026; BEACH301 (ACH) interim results 2H 2026.","Appointed Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer in Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126778,"accession_number":"0001193125-25-303162","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-12-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tyra Biosciences appoints Bhavesh Ashar as COO; Bensen becomes Chief Discovery Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bhavesh Ashar appointed COO effective Dec 1, 2025; Daniel Bensen moved to Chief Discovery Officer.","Ashar base salary $550,000; target annual incentive 40% of base.","Granted options to purchase 300,000 shares vesting over 4 years (25% cliff at 1 year).","Severance provisions: 12 months salary plus target bonus if terminated without cause outside change in control.","Ashar previously Chief Commercial Officer at SpringWorks Therapeutics (Merck KGaA)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126777,"accession_number":"0001193125-25-266916","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q3 net loss $29.9M; cash $274.9M; dabogratinib trials on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities of $274.9M as of Sep 30, 2025; runway through at least 2027.","Q3 net loss $29.9M vs $24.0M in Q3 2024; R&D spend $25.5M (up from $22.7M) on trial initiations.","First patients dosed in Phase 2 achondroplasia (BEACH301) and NMIBC (SURF302) studies; interim data expected 2026.","FDA cleared IND for dabogratinib in low-grade upper tract urothelial carcinoma (SURF303); Phase 2 start in 2026.","Upcoming milestones: SURF302 3-month CR data in 1H 2026; BEACH301 safety sentinel results in 2H 2026."],"consensus_eps_estimate":-0.5075,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143569,"accession_number":"0001193125-25-185553","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tyra Biosciences doses first child in Phase 2 achondroplasia study of dabogratinib","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First child dosed in BEACH301 Phase 2 study of dabogratinib (formerly TYRA-300) for achondroplasia.","Initial results from safety sentinel cohort expected in second half of 2026.","Dabogratinib is an FGFR3 inhibitor, Tyra's lead candidate for achondroplasia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143568,"accession_number":"0000950170-25-108876","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q2 2025 cash $296.3M; dosed first patient in SURF302 NMIBC trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and marketable securities of $296.3M as of June 30, 2025; runway through at least 2027.","Q2 net loss of $28.1M, vs $18.7M in Q2 2024; R&D expenses $24.3M (up from $18.0M).","Dosed first patient in SURF302 Phase 2 study of dabogratinib for FGFR3-altered intermediate-risk NMIBC.","BEACH301 Phase 2 achondroplasia study now enrolling safety sentinel cohort; dose first child expected 3Q 2025.","Initial three-month complete response data from SURF302 expected in first half 2026."],"consensus_eps_estimate":-0.5393,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161761,"accession_number":"0001193125-25-152016","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tyra Biosciences doses first patient in Phase 2 study of TYRA-300 for low-grade, intermediate risk NMIBC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SURF302 open-label Phase 2 study of TYRA-300 in FGFR3-altered low-grade IR NMIBC; up to 90 participants at US sites.","Primary endpoint: complete response rate at three months; initial CR data expected first half 2026.","Patients randomized to 50 mg QD or 60 mg QD; additional dosing cohort may be evaluated.","TYRA-300 also being studied in pediatric achondroplasia in BEACH301 Phase 2; first child dosing expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161760,"accession_number":"0001193125-25-130670","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tyra Biosciences stockholders elect three Class I directors and ratify EY as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Todd Harris, Adele Gulfo, and S. Michael Rothenberg elected as Class I directors for three-year terms.","Harris received 33,878,966 for and 6,434,333 withheld; Gulfo 40,310,667 for and 2,632 withheld; Rothenberg 33,731,963 for and 6,581,336 withheld.","Ratification of Ernst & Young as auditor for FY2025: 45,356,001 for, 235 against, 643 abstain; no broker non-votes.","Broker non-votes on director election totaled 5,043,580 for each director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161759,"accession_number":"0000950170-25-066924","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q1 net loss $28.1M; cash $318.9M; BEACH301 achondroplasia study open","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $28.1M vs $18.2M in Q1 2024; R&D expense $25.0M (up 45% YoY) driven by clinical start-up costs.","Cash, equivalents, and marketable securities $318.9M as of March 31, 2025; runway through at least 2027.","BEACH301 Phase 2 study of TYRA-300 for pediatric achondroplasia now enrolling safety sentinel cohort.","SURF431 Phase 1 study of TYRA-430 (FGFR4/3 inhibitor) in HCC initiated; first patient dosed.","SURF302 Phase 2 NMIBC study of TYRA-300 expected to dose first patient in Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179850,"accession_number":"0000950170-25-046064","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences reports $86.5M net loss for 2024; cash runway through 2027; three INDs cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and marketable securities $341.4M at YE 2024 (up from $203.5M), providing runway through at least 2027.","Full-year 2024 net loss $86.5M vs $69.1M in 2023; R&D expenses $80.1M vs $62.5M.","TYRA-300 showed 54.5% confirmed PR (6/11) at ≥90mg QD in FGFR3+ mUC patients (SURF301).","Three INDs cleared: TYRA-300 Phase 2 for NMIBC (SURF302) and ACH (BEACH301), and TYRA-430 Phase 1 (SURF431).","First patient dosing expected Q2 2025 for BEACH301 (achondroplasia), SURF302 (NMIBC), and SURF431 (HCC)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179849,"accession_number":"0001193125-25-015646","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2025-01-29T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tyra Biosciences appoints Adele M. Gulfo to board; Nina Kjellson resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nina Kjellson resigned from board and Compensation Committee effective Jan 29, 2025, not due to disagreement.","Adele M. Gulfo appointed as Class I director and to Compensation Committee effective same date.","Gulfo, 62, former CEO Sumitomo Pharma America Biopharma Commercial Unit (Jul 2023-Oct 2024) and prior roles at Sumitovant, Roivant, Mylan, Pfizer, AstraZeneca.","Gulfo received options for 37,200 shares vesting over 36 months and cash compensation per non-employee director program.","Board determined Gulfo independent under Nasdaq rules; no material transactions with company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196633,"accession_number":"0000950170-24-123286","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q3 net loss $24M; cash $360M; positive interim TYRA-300 mUC data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $24.0M in Q3 2024 vs $21.2M in Q3 2023; R&D expense $22.7M, up from $19.3M.","Cash, equivalents, and marketable securities $360.1M; runway through at least 2026.","TYRA-300 interim data: at ≥90 mg QD, 6/11 (54.5%) mUC patients with FGFR3+ had confirmed PR; 100% disease control.","FDA cleared IND for Phase 2 achondroplasia study (BEACH301); first child dosing expected Q1 2025.","Appointed Doug Warner as Chief Medical Officer, effective September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196632,"accession_number":"0001193125-24-244590","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tyra Biosciences receives FDA clearance for Phase 2 trial of TYRA-300 in achondroplasia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for TYRA-300 Phase 2 trial (BEACH301) in children with achondroplasia ages 3-10.","BEACH301 is multicenter, open-label, dose-escalation/dose-expansion with two cohorts (naïve and prior therapy), up to 10 per dose level.","Primary endpoints: safety/tolerability and annualized growth velocity; secondary: height z-score, proportionality, PK.","First patient dosing expected Q1 2025; also plans IND for TYRA-300 in NMIBC by year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196631,"accession_number":"0001193125-24-243475","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-10-25T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Tyra Biosciences reports interim TYRA-300 data: 54.5% confirmed PR in FGFR3+ mUC at ≥90 mg QD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Aug 15, 2024, 41 patients enrolled in SURF301 Phase 1; 6/11 (54.5%) FGFR3+ mUC patients at ≥90 mg QD achieved confirmed partial response, 3 ongoing.","100% disease control rate (PR + stable disease) observed in patients at ≥90 mg QD.","TYRA-300 generally well-tolerated; no Gr4+ TRAEs, 1 DLT (Gr3 diarrhea) and 1 discontinuation (Gr3 ALT) at 90 mg QD.","Director Siddarth Subramony resigned from Board and Compensation Committee effective Oct 24, 2024, not due to any disagreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196630,"accession_number":"0001193125-24-239650","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-10-18T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Tyra Biosciences to exchange 3M shares for pre-funded warrants with Boxer Capital, RA Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Boxer Capital exchanges 2M shares, RA Capital exchanges 1M shares of common stock.","Each pre-funded warrant has $0.001 exercise price, immediate exercisability, no expiration.","Exchange expected to close on or before October 22, 2024.","Warrants include beneficial ownership limitations of 9.99% or 19.99% at holder's election."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212929,"accession_number":"0000950170-24-092756","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q2 net loss $18.7M; cash remains $373.8M; IND cleared for TYRA-430; ACH IND on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss $18.7M ($13.3M in Q2 2023); R&D $18.0M; cash $373.8M, runway through at least 2026.","FDA cleared IND for TYRA-430 (FGFR4/3 biased inhibitor) for Phase 1 in HCC and other solid tumors.","TYRA-300: preclinical proof-of-concept in hypochondroplasia; ACH IND submission on track for 2H24.","CMO Hiroomi Tada to depart by year-end; external search underway; S&T Committee guiding transition.","SURF301 Phase1 initial results for TYRA-300 expected at a scientific congress in 2H24."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232005,"accession_number":"0001193125-24-151705","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["3.03","5.03","5.07","9.01"],"status":"ready","headline":"Tyra Biosciences shareholders approve officer exculpation amendment to charter","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment eliminates personal liability of officers for monetary damages for breach of fiduciary duty under Delaware law.","Three Class III directors elected: Melissa McCracken, Jake Simson, Rehan Verjee.","Ratification of Ernst & Young as independent auditor for fiscal year ending December 31, 2024.","Amendment effective upon filing with Delaware Secretary of State on May 29, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232004,"accession_number":"0000950170-24-056935","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q1 net loss $18.2M; cash $382.5M; TYRA-300 on track for 2H24 milestones","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.2M in Q1 2024 vs $11.9M in Q1 2023; R&D expenses $17.2M.","Cash, equivalents, and marketable securities of $382.5M as of March 31, 2024; funding through at least 2026.","Closed $200M private placement in Feb 2024.","TYRA-300 on track for ACH IND submission and initial SURF301 results in 2H24.","Appointed Susan Moran, M.D. and S. Michael Rothenberg, M.D., Ph.D. to board."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":232003,"accession_number":"0001193125-24-133170","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Tyra Biosciences appoints Drs. Moran and Rothenberg to Board; Dr. Chen resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Isan Chen resigned from Board and Compensation Committee effective May 7, 2024, with no disagreement.","Board expanded from nine to ten and appointed Susan Moran (former CMO, RayzeBio) and S. Michael Rothenberg (CMO, insitro) as directors.","Moran appointed to Compensation and Science/Technology Committees; Rothenberg to Science/Technology Committee.","Each new director received options for 37,200 shares vesting over 36 months plus cash compensation.","Both directors are deemed independent under Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250283,"accession_number":"0000950170-24-033455","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences reports FY 2023 net loss $69.1M; $403.5M cash after $200M PIPE","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2023 net loss $22.8M vs $12.9M; FY net loss $69.1M vs $55.3M.","Closed $200M PIPE in Feb 2024; pro-forma cash $403.5M to fund operations through at least 2026.","TYRA-300 Phase 1 SURF301 initial data expected 2H 2024; Phase 2 IND for achondroplasia on track for 2H 2024.","FDA granted Rare Pediatric Disease Designation for TYRA-300 in achondroplasia (Jan 2024).","Initiated SURF201 Phase 1 study for TYRA-200 in FGFR2-altered cholangiocarcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250282,"accession_number":"0001193125-24-023367","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Tyra Biosciences announces $200M private placement led by RA Capital at $13.01/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of approximately $200 million from sale of ~15.4 million shares/pre-funded warrants at $13.01 per share.","Financing led by RA Capital Management with participation from Boxer Capital, BVF Partners, Nextech, OrbiMed, 5AM Ventures.","Proceeds to advance clinical development of TYRA-300 and TYRA-200, preclinical programs, and for working capital.","PIPE expected to close on February 6, 2024, subject to customary closing conditions.","Company to file resale registration statement with SEC within 45 days after closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250281,"accession_number":"0001193125-24-021953","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA grants Rare Pediatric Disease Designation to Tyra Biosciences' TYRA-300 for achondroplasia","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Rare Pediatric Disease Designation to TYRA-300, an oral FGFR3 inhibitor, for achondroplasia.","If NDA approved, Tyra may receive a Priority Review Voucher (PRV) that can be sold or transferred.","Company plans to submit IND in H2 2024 for a randomized Phase 2 trial in children with achondroplasia.","RPD Designation is for diseases affecting <200,000 in US and primarily individuals under 18 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267837,"accession_number":"0001193125-23-301829","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-12-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tyra Biosciences dosed first patient in SURF201 for TYRA-200; TYRA-300 Part A clears dose cohorts; plans ACH IND H2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in SURF201 Phase 1 study of TYRA-200 for FGFR2-altered cholangiocarcinoma and advanced solid tumors.","SURF301 Part A dose escalation cleared multiple cohorts above anticipated dose for Phase 2 achondroplasia study.","Expansion cohorts in SURF301 Part B at dose levels anticipated for oncology evaluation.","Tyra plans to submit initial SURF301 Phase 1 results for a scientific congress in 2024.","Company plans to submit IND for TYRA-300 in pediatric achondroplasia in H2 2024, starting with ages 5-12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267836,"accession_number":"0000950170-23-060235","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences reports Q3 net loss $21.2M; cash $215.7M; advances TYRA-300 and TYRA-200 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2023 net loss $21.2M vs $12.5M YoY; R&D expenses $19.3M (prior $10.9M).","Cash and equivalents $215.7M as of Sept 30, 2023; funds operations for at least two years.","SURF301 Phase 1/2 for TYRA-300 (FGFR3 inhibitor) dose escalation ongoing; preclinical achondroplasia data positive.","TYRA-200 Phase 1 in FGFR2-altered cholangiocarcinoma on track to dose first patient by YE 2023.","FDA granted TYRA-300 Orphan Drug Designation for achondroplasia in July 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267835,"accession_number":"0001193125-23-264152","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-10-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Tyra Biosciences amends bylaws to adopt universal proxy rules and enhance stockholder proposal disclosure","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amended bylaws effective Oct 26, 2023.","Amendments require compliance with SEC Rule 14a-19 for proxy solicitations supporting non-Board nominees.","Enhanced procedural and disclosure requirements for stockholder director nominations and other business proposals.","Includes technical, modernizing and clarifying changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":285062,"accession_number":"0000950170-23-041368","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q2 net loss $13.3M; orphan drug designation for TYRA-300 in achondroplasia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $13.3M vs $15.1M Q2 2022; cash & equivalents $232.4M as of June 30.","FDA granted Orphan Drug Designation for TYRA-300 for achondroplasia in July 2023.","SURF301 Phase 1/2 oncology study enrollment ongoing in Part A and Part B at U.S., EU, Australia sites.","TYRA-200 Phase 1 study in intrahepatic cholangiocarcinoma on track to dose first patient 2H 2023.","Strengthened leadership: appointed Dr. Michael Bober as VP Clinical Development and Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304885,"accession_number":"0001193125-23-159845","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tyra Biosciences stockholders elect three Class II directors, ratify E&Y as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders elected Isan Chen (37.3M for), Gilla Kaplan (37.6M for), and Robert More (37.6M for) as Class II directors to serve until 2026.","Ratification of Ernst & Young as independent auditor for FY 2023 passed with 40,984,756 for, 625 against, and 1,819 abstentions.","Broker non-votes were 3,109,065 for director elections and 0 for auditor ratification.","Annual meeting held on May 31, 2023; all proposals approved by substantial majorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304884,"accession_number":"0000950170-23-017846","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q1 net loss $11.9M, cash $241.7M; programs advance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.9M vs $14.8M YoY; R&D expense $10.4M, G&A $3.9M.","Cash and equivalents $241.7M, expected to fund operations >2 years.","SURF301 Phase 1/2 of TYRA-300 for FGFR3+ tumors continues enrolling patients.","TYRA-300 development expanded into achondroplasia; IND submission targeted in 2024.","TYRA-200 IND cleared by FDA; Phase 1 for cholangiocarcinoma on track for 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324399,"accession_number":"0000950170-23-009166","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences reports 2022 net loss of $55.3M; cash $251.2M; TYRA-300 in clinic for oncology and achondroplasia","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net loss $12.9M vs $9.9M in Q4 2021; full year net loss $55.3M vs $26.3M.","Cash and equivalents $251.2M as of Dec 31, 2022; provides >2 years runway.","Initiated patient dosing with TYRA-300 in Phase 1/2 SURF301 oncology study in Nov 2022.","Expanded TYRA-300 development into achondroplasia; IND planned for Phase 2 in 2024.","FDA cleared IND for TYRA-200 Phase 1 study in FGFR-resistant cholangiocarcinoma; first patient expected 2H 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":324398,"accession_number":"0001193125-23-055156","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Tyra Biosciences expands TYRA-300 into achondroplasia with positive preclinical data; TYRA-200 IND cleared","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TYRA-300 increased body length by 17.6% in FGFR3 Y367C/+ mice (p<0.0001); femur +24.4%, tibia +38.3%, L4-L6 +23.9%.","Company plans to submit IND for Phase 2 study in pediatric achondroplasia in 2024.","FDA cleared IND for TYRA-200, an FGFR1/2/3 inhibitor; first patient dosing expected H2 2023.","Compensation Committee adopted annual incentive plan; CEO target bonus 50% of base salary, other execs 40%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342292,"accession_number":"0001193125-22-293899","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-11-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Tyra Biosciences doses first patient in Phase 1/2 SURF301 study of TYRA-300","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in SURF301 Phase 1/2 study of TYRA-300 for FGFR3+ advanced solid tumors.","Multi-center, open-label study to determine optimal/MTD/RP2D and evaluate antitumor activity.","Study targets both untreated and resistant FGFR3+ solid tumors; announced Nov 29, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342291,"accession_number":"0000950170-22-021888","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q3 net loss widens to $12.5M; CFO van den Boom to step down, Fuhrman appointed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.5M in Q3 2022 vs $6.6M a year ago; cash and equivalents $263.2M.","R&D expenses $10.9M (up from $5.5M); G&A expenses $2.7M (up from $1.2M).","CFO Esther van den Boom resigns effective Dec 31, 2022; will provide transitional consulting services.","Alan Fuhrman appointed CFO effective Jan 1, 2023; base salary $440k, target bonus 40%, equity grants.","SURF301 study ongoing; IND for TYRA-200 expected by year-end 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342290,"accession_number":"0001193125-22-256710","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-10-03T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Tyra Biosciences enters $150M ATM equity offering facility with Virtu Americas","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $150M of common stock at prevailing market prices through Agent Virtu Americas LLC.","Agent receives commission up to 3.0% of gross proceeds; no obligation for Company to sell any shares.","Shares issued under shelf registration statement filed with SEC on October 3, 2022.","Either party may terminate the Sales Agreement at any time on prior written notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359046,"accession_number":"0000950170-22-014777","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences reports Q2 net loss of $15.1M; FDA clears IND for TYRA-300","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2022 net loss $15.1M vs $5.5M in Q2 2021; R&D expense $12.0M vs $4.4M.","Cash and cash equivalents $275.1M as of June 30, 2022, sufficient to fund operations.","FDA cleared IND for TYRA-300 (FGFR3 inhibitor) to begin Phase 1/2 SURF301 study in metastatic urothelial carcinoma.","IND for TYRA-200 (FGFR2 inhibitor) on track for submission in 2H 2022 with initial focus on intrahepatic cholangiocarcinoma.","Key leadership hires: Sarah Honig (VP Corp Dev) and Ali Fawaz (General Counsel/Secretary)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377857,"accession_number":"0001193125-22-173822","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Tyra Biosciences stockholders elect three Class I directors and ratify Ernst & Young as auditor at 2022 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Todd Harris, Nina Kjellson, and Siddarth Subramony elected as Class I directors with ~30.05M votes each; broker non-votes ~1.09M.","Ratification of Ernst & Young as independent auditor for FY2022 approved with 31,551,343 votes for, 0 against, 927 abstentions.","Meeting held on June 13, 2022; all director nominees and auditor ratification passed without opposition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":377856,"accession_number":"0001193125-22-142331","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q1 net loss $14.8M; cash $292.5M; IND filings on track for 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.8M in Q1 2022 vs $4.2M in Q1 2021, driven by higher R&D and G&A expenses.","R&D expense $9.6M (up from $3.5M); G&A expense $5.2M (up from $0.7M).","Cash and equivalents $292.5M as of March 31, 2022, supporting pipeline into clinical stage.","IND for TYRA-300 (FGFR3 inhibitor) expected mid-2022; TYRA-200 (FGFR2) IND in H2 2022.","Pipeline includes programs in achondroplasia, RET, and FGFR4-driven cancers."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396166,"accession_number":"0001193125-22-064358","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2022-03-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Tyra Biosciences Q4 net loss $9.9M, cash $302.2M; IND filings on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 net loss $9.9M vs $3.7M; full-year net loss $26.3M vs $9.3M.","Cash and cash equivalents $302.2M at year-end 2021; no revenue reported.","IND for TYRA-300 (FGFR3) expected mid-2022; TYRA-200 (FGFR2) in H2 2022.","Appointed Allison Kemner as VP Clinical Sciences and Operations in Q4 2021.","Added to Russell 2000 Index in December 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415182,"accession_number":"0001193125-21-318435","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2021-11-03T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Tyra Biosciences Q3 net loss $6.6M; cash $312.8M post-$198.7M IPO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $312.8M as of Sep 30, 2021, up from $15.2M at Dec 31, 2020.","Net loss of $6.6M ($0.72/sh) for Q3 2021 vs $2.3M ($1.47/sh) in Q3 2020.","Nominated TYRA-200 (FGFR2 inhibitor) for clinical development; IND expected 2H 2022.","Appointed Esther van den Boom CFO, John Healy GC, Allison Kemner VP, Rehan Verjee to board.","R&D expenses $5.5M (up from $1.9M) driven by pipeline advancement and personnel costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.63,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433087,"accession_number":"0001193125-21-276124","cik":1863127,"company_name":"Tyra Biosciences, Inc.","ticker":"TYRA","form_type":"8-K","filed_at":"2021-09-17T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Tyra Biosciences closes IPO of 12.42M shares at $16, raising $198.7M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO of 12.42M shares (includes full underwriter option) at $16.00/share closed on Sep 17, 2021.","Gross proceeds of $198.7M before underwriting discounts and offering expenses.","Amended charter to increase authorized common to 500M shares, authorize 50M preferred shares, and establish classified board.","Bylaws amended to set procedures for stockholder proposals and director nominations effective upon IPO closing.","Company is an emerging growth company under the JOBS Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1962522520.500452,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}